Puberty; Precocious, Central
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Foresee PharmaceuticalsDE - Newark
1 program1
Leuprolide Mesylate, Subcutaneous injection of 42 mg LeuprolidePhase 31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2023
2024
2025
2026
Foresee PharmaceuticalsLeuprolide Mesylate, Subcutaneous injection of 42 mg Leuprolide
Clinical Trials (1)
Total enrollment: 93 patients across 1 trials
Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty
Start: Jun 2023Est. completion: Jun 202693 patients
Phase 3Active Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.